Abbott Laboratories
ABT

$201.08 B
Marketcap
$115.93
Share price
Country
$-1.20
Change (1 day)
$121.64
Year High
$99.71
Year Low
Categories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

marketcap

P/E ratio for Abbott Laboratories (ABT)

P/E ratio as of 2023: 33.35

According to Abbott Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.35. At the end of 2022 the company had a P/E ratio of 27.76.

P/E ratio history for Abbott Laboratories from 1985 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 33.35
2022 27.76
2021 35.33
2020 43.19
2019 41.65
2018 53.62
2017 208.61
2016 40.41
2015 14.95
2014 29.72
2013 23.04
2012 8.29
2011 8.93
2010 7.66
2009 6.95
2008 8.07
2007 11.49
2006 20.76
2005 8.68
2004 10.76
2003 11.89
2002 10.05
2001 25.07
2000 12.10
1999 10.26
1998 14.51
1997 10.99
1996 9.43
1995 8.82
1994 7.85
1993 7.89
1992 9.23
1991 12.09
1990 9.04
1989 7.94
1988 6.43
1987 7.74
1986 8.83
1985 7.68